Peptide Initiative

Peptides · Peptide comparison

Defensin (HBD-2) vs Defensin (HBD-3)

Inducible human beta-defensin antimicrobial peptide (41 amino acids) that kills bacteria through membrane disruption at MIC 50 μg/mL against S. aureus, recruits dendritic cells and T cells via CCR6 receptor chemotaxis, and serves as a critical bridge between innate and adaptive immunity — upregulated up to 100-fold during infection and inflammation

Most potent human beta-defensin (45 amino acids) with unique salt-insensitive antimicrobial activity — kills MRSA at MIC 0.5-1.0 μg/mL regardless of salt concentration, disrupts biofilms at 4-8 μg/mL, and retains full bactericidal function even without its disulfide bonds — representing a next-generation antimicrobial peptide template for combating antibiotic resistance

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeDefensin (HBD-2)1–1 mcg/mLDefensin (HBD-3)200–200 mcg/mL
FrequencyDefensin (HBD-2)As neededDefensin (HBD-3)As needed
AdministrationDefensin (HBD-2)Topical application (research/wound care)Defensin (HBD-3)Topical application (research/wound care)
Cycle lengthDefensin (HBD-2)Ongoing/indefiniteDefensin (HBD-3)Ongoing/indefinite
Onset speedDefensin (HBD-2)Rapid (hours to days)Defensin (HBD-3)Rapid (hours to days)
Evidence levelDefensin (HBD-2)Moderate human trials (Phase 1-2)Defensin (HBD-3)Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Germ Fighting

Defensin (HBD-2)94%
Defensin (HBD-3)No recorded rating

Immune Signaling

Defensin (HBD-2)91%
Defensin (HBD-3)No recorded rating

Wound Defense

Defensin (HBD-2)87%
Defensin (HBD-3)No recorded rating

Fighting Drug-Resistant Bacteria

Defensin (HBD-2)No recorded rating
Defensin (HBD-3)96%

Wound Healing

Defensin (HBD-2)No recorded rating
Defensin (HBD-3)88%

Immune System Support

Defensin (HBD-2)No recorded rating
Defensin (HBD-3)82%

Technical data

Compound specifications

Defensin (HBD-2)

Molecular formula
Approximately C185H290N54O57S6 (41-amino acid peptide with 3 disulfide bonds)
Molecular weight
~4,328 Da (mature peptide)
Half-life
Short plasma half-life (minutes); locally stable at wound and epithelial sites due to disulfide-bonded structure; degraded by metalloproteinases in chronic wound environments
Bioavailability
Topical application provides local antimicrobial activity; three disulfide bonds confer resistance to proteolytic degradation; salt-sensitive — activity reduced above 150 mM NaCl; not intended for oral or systemic delivery
CAS number
Not assigned (endogenous human peptide; research-grade available from multiple suppliers)

Defensin (HBD-3)

Molecular formula
Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds)
Molecular weight
~5,155 Da (mature peptide)
Half-life
Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications
Bioavailability
Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery
CAS number
Not assigned (endogenous human peptide; research-grade available from peptide suppliers)

Protocols

Dosing compared

Defensin (HBD-2)

Topical

  • 1 µg/mL applied to the wound (e.g. 28 µL of a 1 µg/mL solution, or loaded into a wound dressing)Per dressing change in the study · Preclinical study durationHBD-2 is a research-only peptide with no human dosing protocol. This amount comes from a preclinical diabetic-wound study where it was applied to the wound surface and helped clear MRSA infection [6]. Human use has not been established.

Defensin (HBD-3)

Topical

  • 200 µg/mL applied to the wound, about 4 µg per dose (20 µL)Every 2 days in the study · Until wound healed (study setting)HBD-3 is a research-only peptide with no human dosing protocol. No published study gives a topical peptide dose: the infected-diabetic-wound study on this page delivered hBD-3 by gene transfer, not as an applied peptide [6], so this amount is unsourced. Human use has not been established.

Applications

Best suited for

Defensin (HBD-2)

Research into novel topical antimicrobial therapies for skin infections and chronic wounds
Defensin (HBD-2) is particularly well-suited for individuals focused on research into novel topical antimicrobial therapies for skin infections and chronic wounds. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Biomarker development for inflammatory skin disease monitoring (psoriasis, atopic dermatitis)
Defensin (HBD-2) is particularly well-suited for individuals focused on biomarker development for inflammatory skin disease monitoring (psoriasis, atopic dermatitis). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding innate-adaptive immune crossover mechanisms in mucosal defense
Defensin (HBD-2) is particularly well-suited for individuals focused on understanding innate-adaptive immune crossover mechanisms in mucosal defense. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial surfaces and wound dressings incorporating defensin peptides
Defensin (HBD-2) is particularly well-suited for individuals focused on development of antimicrobial surfaces and wound dressings incorporating defensin peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Defensin (HBD-3)

Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and medical device coatings
Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and implant-associated infections
Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Applications requiring antimicrobial activity in physiological or high-salt environments
Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Defensin (HBD-2)

Common

  • Local site irritation
  • Transient inflammatory response
  • Reduced activity in saline environments

Uncommon

  • Localized allergic reaction
  • Inflammatory amplification

Serious

  • No serious adverse effects documented

Defensin (HBD-3)

Common

  • Local site irritation
  • Transient inflammatory response
  • Mild wound bed changes

Uncommon

  • Localized allergic reaction
  • Mild cytotoxicity at high concentrations

Serious

  • No serious adverse effects documented at therapeutic concentrations

Research status

Safety & evidence

Defensin (HBD-2)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Defensin HBD-2 is not FDA-approved and has no completed human clinical trials, with all safety data limited to in vitro mechanistic studies and animal models. Animal toxicology studies show no significant systemic toxicity or organ damage at doses exceeding therapeutic levels. However, human immunological responses to exogenously administered antimicrobial peptides are not fully characterized. Concerns exist regarding potential immune activation, cross-reactivity with self-antigens, and development of antibodies to the synthetic peptide. Bacterial resistance development to defensin-based therapeutics is theoretically possible. No human pharmacokinetics, dose-escalation studies, Phase 1 safety data, or clinical efficacy trials have been conducted.

Contraindications

  • Known hypersensitivity to defensin peptides or formulation components
  • Pregnancy and breastfeeding — insufficient safety data for exogenous defensin administration
  • Active autoimmune skin conditions where defensin overexpression may contribute to pathology (e.g., psoriasis flare)
  • Cystic fibrosis patients — elevated airway NaCl concentrations inactivate HBD-2 antimicrobial activity

Defensin (HBD-3)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist.

Contraindications

  • Known hypersensitivity to defensin peptides or formulation components
  • Pregnancy and breastfeeding — insufficient safety data for exogenous defensin administration
  • Active autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment
  • Severe hepatic or renal impairment — peptide clearance may be altered for any systemic exposure

Decision guide

Which is right for you?

Defensin (HBD-2)

Choose Defensin (HBD-2) if…

  • Research into novel topical antimicrobial therapies for skin infections and chronic wounds
  • Biomarker development for inflammatory skin disease monitoring (psoriasis, atopic dermatitis)
  • Understanding innate-adaptive immune crossover mechanisms in mucosal defense
  • Development of antimicrobial surfaces and wound dressings incorporating defensin peptides

Defensin (HBD-3)

Choose Defensin (HBD-3) if…

  • Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
  • Development of antimicrobial wound dressings and medical device coatings
  • Anti-biofilm strategies for chronic wound infections and implant-associated infections
  • Applications requiring antimicrobial activity in physiological or high-salt environments